Bessemer Group’s Spero Therapeutics SPRO Stock Holding History

Bessemer Group’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-44,100	Closed	-$597K	–	1637
2020 Q2	$597K	Buy	+44,100	New	+$495K	﹤0.01%	923

Other funds holding SPRO

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Bessemer Group's SPRO Position: Q3 2020 in Review

Bessemer Group sold out of Spero Therapeutics (SPRO) in Q3 2020, closing a stake of 44,100 shares — an estimated $597K sold.

Bessemer Group first reported a position in SPRO in Q2 2020 and held it in 1 quarter. The position peaked at $597K in Q2 2020. 78 funds tracked by Wall St. Rank hold SPRO as of Q3 2020.

Bessemer Group reported no remaining Spero Therapeutics position as of Q3 2020 after selling out during the quarter.
Bessemer Group sold 44,100 Spero Therapeutics shares in Q3 2020, an estimated $597K.
Bessemer Group first reported a position in Spero Therapeutics in Q2 2020 and held it in 1 quarter.
Bessemer Group's Spero Therapeutics position peaked at $597K in Q2 2020.
78 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.